Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants

Completed

• Conditions: Brain Damage, Chronic

• Registration Number: NCT00544895
• Lead Sponsor: Hannover Medical School

Brief Summary

NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from www.neobrain.eu)

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Study First Submitted: 2007-10-12
• Study First Submitted QC: 2007-10-15
• Study First Posted: 2007-10-16
• Study Completion: 2010-10
• Status Verified: 2011-06
• Last Update Submitted: 2011-06-22
• Last Update Posted: 2011-06-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Gestational age < 28 weeks

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Brain white matter damage (WMD, defined by MRI ,US, EEG)	during stay in NICU and until discharge

Secondary Outcome Measures

Name	Time	Method
Developmental assessment	at 2 years of age

Trial Locations

Locations (12)

Medizinische Universität Innsbruck; 🇦🇹 Innsbruck, Austria

Hôpital Robert Debré; 🇫🇷 Paris, France

Charité, Campus Virchow Klinikum; 🇩🇪 Berlin, Germany

Universität Duisburg-Essen; 🇩🇪 Essen, Germany

Hannover Medical School; 🇩🇪 Hannover, Germany

Fondazione I.R.C.C.S Ospedale Maggiore Policlinico MA.RE.; 🇮🇹 Milano, Italy

Azienda Ospedaliera Universitaria Senese; 🇮🇹 Siena, Italy

Wilhelmina Children's Hospital; 🇳🇱 Utrecht, Netherlands

Perinatal Center; 🇸🇪 Gothenburg, Sweden

University Hospital; 🇸🇪 Lund, Sweden

Scroll for more (2 remaining)